Nautilus Biotechnology Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Operating Expenses: $15.5 million, down 19% year-over-year from $19.1 million.

Research and Development Expenses: $9.6 million, reduced from $12.3 million in Q3 2024.

General and Administrative Expenses: $5.9 million, down from $6.8 million year-over-year.

Net Loss: $13.6 million, improved from $16.4 million in the prior year.

Cash Position: $168.5 million in cash and investments, with a cash burn of $11.0 million in Q3.

Cash Runway: Expected to extend through 2027.

2Strategic Updates and Business Highlights

Nautilus made significant advancements in its scientific platform, particularly in measuring proteoforms with high precision.

Collaborations were established with notable institutions, including the Allen Institute for Brain Science and the Buck Institute for Research on Aging, focusing on Tau proteoforms and their implications in Alzheimer's disease.

The company is preparing for an early access program for its Tau proteoform assay, set to launch in the first half of 2026.

Progress was made in transitioning to a new broadscale assay configuration, aimed at improving platform performance and scalability for a commercial launch anticipated in late 2026.

A market study involving over 250 decision-makers indicated strong customer interest and willingness to invest in Nautilus's differentiated technology.

3Forward Guidance and Outlook

Total operating expenses for 2025 are expected to remain below levels from the past two years, with a gradual increase anticipated as commercialization efforts ramp up.

The early access program is expected to generate initial engagements with academic key opinion leaders, leading to potential revenue and further publications.

The company plans to expand its early access offerings to include broader proteomic capabilities in the second half of 2026.

4Bad News, Challenges, or Points of Concern

While the company has reduced expenses, it does not expect meaningful revenue from early access engagements in 2026, which may delay financial performance.

The transition to commercialization involves inherent risks, including the need for successful validation of the new assay configurations and the competitive landscape in proteomics.

The reliance on collaborations for data generation and validation may pose risks if partnerships do not yield expected results.

5Notable Q&A Insights

Management indicated that operating expenses would increase as they approach commercialization, but specific 2026 forecasts were not provided.

The early access program will begin with Tau proteoform capabilities, with plans to expand into broader proteomic offerings later in 2026.

The company is in the process of building a sales pipeline and anticipates hiring additional sales staff to support commercialization efforts. Overall, Nautilus Biotechnology is making significant strides in its scientific and operational initiatives while maintaining a strong financial position, though challenges remain as it transitions toward commercialization.